ASCO GU 2026: Trastuzumab Deruxtecan in Pretreated Patients with HER2-Expressing Bladder Cancer: Final Results from the Bladder Cancer Cohort in Part 1 of DESTINY-PanTumor02
Trastuzumab deruxtecan shows durable and clinically meaningful activity in HER2‑expressing advanced bladder cancer, achieving an overall objective response rate of ~41% in a heavily pretreated cohort.
In the Phase II, open‑label, single‑arm DESTINY‑PanTumor02 Part 1 (NCT04482309), trastuzumab deruxtecan (T‑DXd) was evaluated in 41 patients with advanced urothelial carcinoma expressing HER2 (35% with IHC 2+, 39% with IHC 3+). The investigator‑assessed overall objective response rate (ORR) was 41.5% (17/41; 95% CI 26.3–57.9), with 56.3% response in IHC 3+ and 40.0% in IHC 2+ tumors. Median duration of response was 9.5 months, progression‑free survival 7.0 months and overall survival 12.8 months. The safety profile was consistent with prior experience, with interstitial lung disease/pneumonitis observed in 9.8% of patients.
HER2‑positive urothelial carcinoma remains a therapeutic challenge; these results provide a promising new systemic option for patients who have exhausted standard cisplatin‑based and immunotherapeutic regimens.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.